The Ntensify™ Production Technology Line is now available!
Ntensify™ are low footprint automated Production Technologies able to synthesize and purify short to very long Messenger RNA's in bulk. Our systems use Quantoom’s reagent pre-mixes to maximize yield, quality, and cost-effectiveness, starting from a chosen DNA template. This produces purified naked RNA, ready to be formulated into a drug product.
Ntensify™ is more than just equipment, it includes:
An optimized process for high performance (yield and quality)
Reagent premixes to ensure the best results
Single use disposables for ease of use
Mini
The Ntensify Mini is an R&D-grade RNA production system suitable for both drug discovery and pre-clinical development.
Midi
The Ntensify Midi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phases I and II.
In less than one day, the system can produce 1 to 5 g of purified RNA in Quantoom’s proprietary reactors using single-use consumables.
Modules are available to upgrade effortlessly from Ntensify Midi to Ntensify Maxi.
Maxi
The Ntensify Maxi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phase III and commercial production.
The Ntensify Maxi is an upgrade of the Midi system to increase the scale. Only minor, easily implementable modifications are required.
The system can produce 33 g of purified RNA per day, in Quantoom’s proprietary reactors using single-use consumables.
Scalability is achieved through an innovative and patented sequential-continuous workflow.
Key facts
Drug discovery: the system can accommodate up to 48 different DNA templates in parallel for the In vitro transcription (IVT) of various RNA sequences at 2 mg of purified output per construct.
Pre-clinical: a single DNA template can be transcribed to produce over 100 mg of the same RNA which is pooled after purification.
In total, the equipment can produce up to 175,000 doses of purified RNA per year (50 µg each)
Key facts
Up to 5 g of purified RNA per day
More than 600 g of purified RNA per year
Up to 7.3 M doses of corresponding drug product (50 µg each)
Key facts
More than 40 batches a year
More than 8 kg of purified RNA per year
Up to 100 M doses of drug product per year (50 µg each)
Mini
The Ntensify Mini is an R&D-grade RNA production system suitable for both drug discovery and pre-clinical development.
Key facts
Pre-clinical: a single DNA template can be transcribed to produce over 100 mg of the same RNA which is pooled after purification.
In total, the equipment can produce up to 175,000 doses of purified RNA per year (50 µg each)
Drug discovery: the system can accommodate up to 192 different DNA templates in parallel for the production of various RNA sequences at 0.5 µg of purified output per construct.
Midi
The Ntensify Midi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phases I and II.
In less than one day, the system can produce 1 to 5 g of purified RNA in Quantoom’s proprietary reactors using single-use consumables.
Modules are available to upgrade effortlessly from Ntensify Midi to Ntensify Maxi
Key facts
Up to 5 g of purified RNA per day
More than 600 g of purified RNA per year
Up to 7.3 M doses of corresponding drug product (50 µg each)
Maxi
The Ntensify Maxi is a GMP-grade RNA production system suitable for the manufacturing of mRNA or saRNA at a scale that is ideal for clinical phase III and commercial production.
The Ntensify Maxi is an upgrade of the Midi system to increase the scale. Only minor, easily implementable modifications are required.
The system can produce 33 g of purified RNA per day, in Quantoom’s proprietary reactors using single-use consumables.
Scalability is achieved through an innovative and patented sequential-continuous workflow.
Key facts
More than 40 batches a year
More than 8 kg of purified RNA per year
Up to 100 M doses of drug product per year (50 µg each)
How Ntensify™ was invented
The COVID-19 pandemic demonstrated the power of RNA vaccines. However, the way RNA is synthesized has not advanced significantly since its early days. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based medicine.
We started with the bold objective to reinvent mRNA production, by breaking down barriers from discovery to development, up to commercial production. We focused efforts on the redesign of the production process, its implementation into reagent pre-mixes and plastic disposables, and the automation of that process through low footprint robotized systems for R&D and GMP uses.
After 18 months of dedicated work from the teams at Quantoom Biosciences, we’re delighted to launch Ntensify™ for RNA production.
How Ntensify™ was invented
The COVID-19 pandemic demonstrated the power of RNA vaccines. However, the way RNA is synthesized has not advanced significantly since its early days. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based medicine.
We started with the bold objective to reinvent mRNA production, by breaking down barriers from discovery to development, up to commercial production. We focused efforts on the redesign of the production process, its implementation into reagent pre-mixes and plastic disposables, and the automation of that process through low footprint robotized systems for R&D and GMP uses.
After 18 months of dedicated work from the teams at Quantoom Biosciences, we’re delighted to launch Ntensify™ for RNA production.
Contact Us
